{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:28:52Z","timestamp":1782991732577,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-024-02498-y","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:51:21Z","timestamp":1736772681000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-8460","authenticated-orcid":false,"given":"Nadeen","family":"Anabtawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deedra","family":"Nicolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daelynn R.","family":"Buelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1409","authenticated-orcid":false,"given":"Shelley","family":"Orwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-369X","authenticated-orcid":false,"given":"Thomas","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9940-0236","authenticated-orcid":false,"given":"Kennedy","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-1000","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-5063","authenticated-orcid":false,"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-1419","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-3252","authenticated-orcid":false,"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2498_CR1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"2498_CR2","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6:e8.","journal-title":"Oncol Rev"},{"key":"2498_CR3","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","volume":"15","author":"S Meshinchi","year":"2009","unstructured":"Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15:4263\u20139.","journal-title":"Clin Cancer Res"},{"key":"2498_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/sci.2017.05.04","volume":"4","author":"Y Chen","year":"2017","unstructured":"Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, et al. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017;4:48.","journal-title":"Stem Cell Investig"},{"key":"2498_CR5","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532\u201342.","journal-title":"Blood"},{"key":"2498_CR6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E, Erhardt S, L\u00fcbbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96:1993\u20132003.","journal-title":"Ann Hematol"},{"key":"2498_CR7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"key":"2498_CR8","volume":"13","author":"S Li","year":"2023","unstructured":"Li S, Li N, Chen Y, Zheng Z, Guo Y. FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis. Front Oncol. 2023;13:1086846.","journal-title":"Front Oncol"},{"key":"2498_CR9","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1182\/bloodadvances.2023011916","volume":"7","author":"J Tamburini","year":"2023","unstructured":"Tamburini J, Mouche S, Larrue C, Duployez N, Bidet A, Salotti A, et al. Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia. Blood Adv. 2023;7:7576\u201380.","journal-title":"Blood Adv"},{"key":"2498_CR10","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1111\/jcmm.17608","volume":"26","author":"CE Jensen","year":"2022","unstructured":"Jensen CE, Montgomery ND, Galeotti J, Foster MC, Zeidner JF. Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia. J Cell Mol Med. 2022;26:6079\u201382.","journal-title":"J Cell Mol Med"},{"key":"2498_CR11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862991","volume":"12","author":"S Stasik","year":"2022","unstructured":"Stasik S, Kramer M, Zukunft S, R\u00f6llig C, Baldus CD, Platzbecker U, et al. Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD. Front Oncol. 2022;12:862991.","journal-title":"Front Oncol"},{"key":"2498_CR12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.18877","volume":"202","author":"S-S Ge","year":"2023","unstructured":"Ge S-S, Qiu Q-C, Dai H-P, Shen X-D, Wu T-M, Du J-H, et al. Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. Br J Haematol. 2023;202:539\u201349.","journal-title":"Br J Haematol"},{"key":"2498_CR13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2004.04808.x","volume":"124","author":"DL Stirewalt","year":"2004","unstructured":"Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124:481\u20134.","journal-title":"Br J Haematol"},{"key":"2498_CR14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2006.07.020","volume":"31","author":"M Syampurnawati","year":"2007","unstructured":"Syampurnawati M, Tatsumi E, Furuta K, Hayashi Y. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene. Leuk Res. 2007;31:877.","journal-title":"Leuk Res"},{"key":"2498_CR15","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","volume":"107","author":"C Reindl","year":"2006","unstructured":"Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107:3700\u20137.","journal-title":"Blood"},{"key":"2498_CR16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2007.11.005","volume":"12","author":"S Fr\u00f6hling","year":"2007","unstructured":"Fr\u00f6hling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12:501\u201313.","journal-title":"Cancer Cell"},{"key":"2498_CR17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/bloodadvances.2020002876","volume":"5","author":"DJ Young","year":"2021","unstructured":"Young DJ, Nguyen B, Zhu R, Seo J, Li L, Levis MJ, et al. Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. Blood Adv. 2021;5:2285\u201393.","journal-title":"Blood Adv"},{"key":"2498_CR18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl J Med. 1994;331:896\u2013903.","journal-title":"N. Engl J Med"},{"key":"2498_CR19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V89.3.780","volume":"89","author":"JO Moore","year":"1997","unstructured":"Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89:780\u20138.","journal-title":"Blood"},{"key":"2498_CR20","first-page":"460","volume":"78","author":"CA Schiffer","year":"1991","unstructured":"Schiffer CA, Davis RB, Schulman P, Cooper B, Coyle T, Lee E, et al. Intensive post remission therapy of acute myeloid leukemia (AML) with cytoxan\/etoposide (CY\/VP16) and diazaquone\/mitoxantrone (AZQ\/MITO). Blood. 1991;78:460. (abstract 1829).","journal-title":"Blood"},{"key":"2498_CR21","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","volume":"22","author":"JE Kolitz","year":"2004","unstructured":"Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol. 2004;22:4290\u2013301.","journal-title":"J Clin Oncol"},{"key":"2498_CR22","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","volume":"105","author":"JO Moore","year":"2005","unstructured":"Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105:3420\u20137.","journal-title":"Blood"},{"key":"2498_CR23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2009-07-229492","volume":"116","author":"JE Kolitz","year":"2010","unstructured":"Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413\u201321.","journal-title":"Blood"},{"key":"2498_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","volume":"31","author":"W Blum","year":"2017","unstructured":"Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017;31:34\u20139.","journal-title":"Leukemia"},{"key":"2498_CR25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"2498_CR26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/leu.2017.86","volume":"31","author":"AK Eisfeld","year":"2017","unstructured":"Eisfeld AK, Mr\u00f3zek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211\u20138.","journal-title":"Leukemia"},{"key":"2498_CR27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/bioinformatics\/btw028","volume":"32","author":"KW Kroll","year":"2016","unstructured":"Kroll KW, Eisfeld AK, Lozanski G, Bloomfield CD, Byrd JC, Blachly JS. MuCor: mutation aggregation and correlation. Bioinformatics. 2016;32:1557\u20138.","journal-title":"Bioinformatics"},{"key":"2498_CR28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fonc.2019.00851","volume":"9","author":"A Petrackova","year":"2019","unstructured":"Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol. 2019;9:851.","journal-title":"Front Oncol"},{"key":"2498_CR29","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","volume":"19","author":"SD Baker","year":"2013","unstructured":"Baker SD, Zimmerman EI, Wang Y-D, Orwick S, Zatechka DS, Buaboonnam J, et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD\u2013positive acute myeloid leukemia. Clin Cancer Res. 2013;19:5758\u201368.","journal-title":"Clin Cancer Res"},{"key":"2498_CR30","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","volume":"122","author":"EI Zimmerman","year":"2013","unstructured":"Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD\u2212positive acute myeloid leukemia. Blood. 2013;122:3607\u201315.","journal-title":"Blood"},{"key":"2498_CR31","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acsomega.7b00144","volume":"2","author":"JA Jarusiewicz","year":"2017","unstructured":"Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, et al. Discovery of a diaminopyrimidine FLT3 inhibitor active against acute myeloid leukemia. ACS Omega. 2017;2:1985\u20132009.","journal-title":"ACS Omega"},{"key":"2498_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The Structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13:169\u2013178.","journal-title":"Mol Cell"},{"key":"2498_CR33","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","volume":"10","author":"T Kawase","year":"2019","unstructured":"Kawase T, Nakazawa T, Eguchi T, Tsuzuki H, Ueno Y, Amano Y, et al. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget. 2019;10:6111\u201323.","journal-title":"Oncotarget"},{"key":"2498_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field. J Chem Theory Comput. 2016;12:405\u201313.","journal-title":"J Chem Theory Comput"},{"key":"2498_CR35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/bs.apcsb.2014.06.002","volume":"96","author":"S Jo","year":"2014","unstructured":"Jo S, Cheng X, Islam SM, Huang L, Rui H, Zhu A, et al. CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues. Adv Protein Chem Struct Biol. 2014;96:235\u201365.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2498_CR36","volume":"435","author":"SJ Park","year":"2023","unstructured":"Park SJ, Kern N, Brown T, Lee J, Im W. CHARMM-GUI PDB manipulator: various PDB structural modifications for biomolecular modeling and simulation. J Mol Biol. 2023;435:167995.","journal-title":"J Mol Biol"},{"key":"2498_CR37","volume":"153","author":"J Lee","year":"2020","unstructured":"Lee J, Hitzenberger M, Rieger M, Kern NR, Zacharias M, Im W. CHARMM-GUI supports the Amber force fields. J Chem Phys. 2020;153:035103.","journal-title":"J Chem Phys"},{"key":"2498_CR38","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J Comput Chem. 2008;29:1859\u201365.","journal-title":"J Comput Chem"},{"key":"2498_CR39","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B, et al. CHARMM: The biomolecular simulation program. J Comput Chem. 2009;30:1545\u20131614.","journal-title":"J Comput Chem"},{"key":"2498_CR40","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084\u201395.","journal-title":"J Chem Theory Comput"},{"key":"2498_CR41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33\u20138.","journal-title":"J Mol Graph"},{"key":"2498_CR42","unstructured":"Schr\u00f6dinger, LLC. Maestro, Schr\u00f6dinger, LLC, New York, NY, 2024."},{"key":"2498_CR43","doi-asserted-by":"crossref","first-page":"W651","DOI":"10.1093\/nar\/gkac365","volume":"50","author":"D Clementel","year":"2022","unstructured":"Clementel D, Del Conte A, Monzon AM, Camagni GF, Minervini G, Piovesan D, et al. RING 3.0: fast generation of probabilistic residue interaction networks from structural ensembles. Nucleic Acids Res. 2022;50:W651\u20136.","journal-title":"Nucleic Acids Res"},{"key":"2498_CR44","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Jain A, McDonald LR, Gambogi C, Lee AL, Dokholyan NV. Mapping allosteric communications within individual proteins. Nat Commun. 2020;11:3862.","journal-title":"Nat Commun"},{"key":"2498_CR45","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.3324\/haematol.2018.209460","volume":"104","author":"P Peterlin","year":"2019","unstructured":"Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, et al. FLT3 ligand plasma levels in acute myeloid leukemia. Haematologica. 2019;104:e240\u20133.","journal-title":"Haematologica"},{"key":"2498_CR46","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","volume":"29","author":"CC Smith","year":"2015","unstructured":"Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29:2390\u20132.","journal-title":"Leukemia"},{"key":"2498_CR47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474\u201388.","journal-title":"Oncogene"},{"key":"2498_CR48","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32:1135\u201346.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02498-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:10:28Z","timestamp":1741104628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02498-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02498-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSB is a consultant for and reported honoraria from KITE, INNATE, Syndax, AstraZeneca and AbbVie. BLP is a consultant for Cornerstone Pharmaceuticals and reported research funding from Ambit Biosciences, Cornerstone, Genentech, Hoffman LaRoche, Jazz Pharmaceuticals, Novartis and Pfizer. WGB reported honoraria from Abbvie, Syndax, and AmerisourceBergen and research funding from Celyad Oncology, Nkarta, Xencor, Forma Therapeutics and Leukemia and Lymphoma Society. GLU is a consultant for AbbVie, Agios, Jazz, GlaxoSmithKline, Genentech, and Novartis; reported honoraria from Astellas and research funding from Macrogenics. JCB consults for Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; receives honoraria from Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; he is a Chairman of the Scientific Advisory Board of Vincerx Pharmaceuticals and a member of advisory committee of Newave; and is a current equity holder of Vincerx Pharmaceuticals. A-KE is the spouse of Christopher J. Walker who is currently employed by Karyopharm Therapeutics. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods in this study were performed in accordance with the U.S. regulatory guidelines and respected the principles outlined in the Declaration of Helsinki. Specifically, the trials complied with the U.S. Food and Drug Administration regulations outlined in 21 CFR Parts 50 and 56, which govern the protection of human subjects and the functioning of Institutional Review Boards (IRBs). Additionally, the trials adhered to the principles of the Common Rule and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines. All patients included in this study provided written informed consent for participation in treatment studies and for the research use of their specimens. Study protocols were reviewed and approved by the IRB at each participating institution (for information about participating institutions see the Supplementary information).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}